Skip to main content

SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures for Cancers

NEW YORK – SkylineDx said Tuesday it has entered an agreement with BioInvent International to characterize gene expression and immunological signatures in the tumors of patients before and after they have been treated with BI-1206, BioInvent's lead therapy candidate for patients with non-Hodgkin lymphoma and solid cancers.

The companies will research and develop predictive immunological signatures to help identify patients who are likely to show clinical responses if treated with BI-1206, Rotterdam, Netherlands-based Skyline Dx said.  

Financial and other terms of the agreement were not disclosed.

Lund, Sweden-based BioInvent has developed a technology platform called First that simultaneously identifies targets and the antibodies that bind to them to generate drug candidates for its clinical development pipeline and for licensing. "Identifying the right patients who are likely to respond to treatment with BI-1206 will constitute a major asset in the development of this promising treatment and, along with FcgRIIB expression levels, should support the extension of its use to other malignancies," BioInvent CEO Martin Welschof said in a statement.